Latest Radius Residential Care (NZX:RAD) News

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Radius Residential Care has syndicated its bank debt, boosting facility limits by NZD 30 million and cutting financing costs by 65 basis points to support its growth plans, including a new care home acquisition and development projects.

Capital raisings, resource updates and Medicare news drove the week’s biggest share moves. The sharpest gains came from silver and tungsten juniors, while the heaviest fall came from a deeply discounted equity raising.

Radius Residential Care delivered a standout FY26 with profit before tax surging 37% to $14.3 million, a 50% hike in its final dividend, and growth fueled by acquisitions and new developments.